Cargando…
Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
Therapeutic drug monitoring (TDM) of anti-TNF-α is an important tool in clinical practice for inflammatory diseases. In this study, we have evaluated the performance of several assays for drug and antidrug antibodies (ADA) measurement in the serum. 50 sera from patients treated with infliximab (IFX)...
Autores principales: | Rissel, Florian, Cazaubon, Yoann, Saffar, Syrine, Altwegg, Romain, Artasone, Mélanie, Lozano, Claire, Vincent, Thierry, Jentzer, Alexandre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299129/ https://www.ncbi.nlm.nih.gov/pubmed/37373525 http://dx.doi.org/10.3390/ijms241210379 |
Ejemplares similares
-
Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018) -
Evaluation of 5 Commercially Available Zika Virus Immunoassays
por: Safronetz, David, et al.
Publicado: (2017) -
External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab
por: Konecki, Celine, et al.
Publicado: (2021) -
Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays
por: De Salazar, Pablo M, et al.
Publicado: (2017) -
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)